Cas:93957-52-9 3-Methyl(E)-7-[3-(4-fluorophenyl)-1-methylethyl-indol-2-yl]-3-hydroxy-5-oxohept-6-enoate manufacturer & supplier

Chemical Name:3-Methyl(E)-7-[3-(4-fluorophenyl)-1-methylethyl-indol-2-yl]-3-hydroxy-5-oxohept-6-enoate

CAS.NO:93957-52-9

Synonyms:MFCD08704643;fhh

Molecular Formula:C₂₅H₂₆FNO₄

Molecular Weight:423.47700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:634.2ºC at 760 mmHg

Density:1.18 g/cm3

Index of Refraction:1.568

PSA:68.53000

Exact Mass:423.18500

LogP:4.92470

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD08704643 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,fhh physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD08704643 Use and application,fhh technical grade,usp/ep/jp grade.

Related News: After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply. 3-Methyl(E)-7-[3-(4-fluorophenyl)-1-methylethyl-indol-2-yl]-3-hydroxy-5-oxohept-6-enoate manufacturer There are more than 4,700 different PFAS chemical compounds, researchers said. Since the 1950s, they have been widely used in a number of consumer products, including stain-repellent fabrics, nonstick cookware, polishes, waxes, paints and cleaning products, according to the U.S. Environmental Protection Agency. 3-Methyl(E)-7-[3-(4-fluorophenyl)-1-methylethyl-indol-2-yl]-3-hydroxy-5-oxohept-6-enoate supplier After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply. 3-Methyl(E)-7-[3-(4-fluorophenyl)-1-methylethyl-indol-2-yl]-3-hydroxy-5-oxohept-6-enoate vendor From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity. 3-Methyl(E)-7-[3-(4-fluorophenyl)-1-methylethyl-indol-2-yl]-3-hydroxy-5-oxohept-6-enoate factory A week before Eli Lilly (LLY.N) disclosed to regulators that the U.S. Justice Department was investigating its New Jersey factory, the drugmaker told employees that its own inquiry, led by an outside law firm, found no evidence of wrongdoing there, according to a company memo reviewed by Reuters.